comparemela.com

Latest Breaking News On - Kimr tsuchimoto - Page 7 : comparemela.com

Monopar Announces New Drug Can - GuruFocus com

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer

Monopar Announces New Drug Candidate, MNPR-202, and Enters into Collaboration Agreement with the National University of Singapore for Preclinical Evaluation in Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery Font : A-A+ WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Nasdaq: MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled “Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation.” Radiopharmaceutical therapy is a promising approach to treat cancer and other diseases using radioactive metals bound with proteins/antibodies to target and kill cells. Actinium-225 (Ac-225) is emerging as a radioactive isotope of choice for radiopharmaceuticals due to favorable properties such as its long half-life, high potency, and induction of localized cell death.

Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery

Share: WILMETTE, Ill. and BELOIT, Wis., May 24, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (NASDAQ:MNPR) and NorthStar Medical Radioisotopes, LLC, today announced the filing of a provisional patent with the U.S. Patent and Trademark Office (USPTO) titled Bio-Targeted Radiopharmaceutical Compositions Containing Ac-225 and Methods of Preparation. Radiopharmaceutical therapy is a promising approach to treat cancer and other diseases using radioactive metals bound with proteins/antibodies to target and kill cells. Actinium-225 (Ac-225) is emerging as a radioactive isotope of choice for radiopharmaceuticals due to favorable properties such as its long half-life, high potency, and induction of localized cell death.

Monopar Therapeutics : Potential to significantly improve the yield of Actinium-based radiopharmaceuticals (Form 8-K)

Monopar Therapeutics : Potential to significantly improve the yield of Actinium-based radiopharmaceuticals (Form 8-K)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.